Trial: Keynote-040

Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

KEYNOTE-040: groundbreaking results for pembrolizumab in head and neck cancer

Post hoc KEYNOTE-040 analysis: pembrolizumab for HNSCC produces lasting immune effect

Post Hoc Analyses of the KEYNOTE-040 Trial on Metastatic Head & Neck Cancer

Is there a use for anti-PDL-1 antibodies in recurrent head and neck cancer?

Improved survival, toxicity & QoL with pembrolizumab in head and neck cancer

Pembrolizumab in the treatment of head and neck cancer: is there more to the story?

The future role of immunotherapy in head and neck cancers

Eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma

Pembrolizumab vs. standard treatment in patients with recurrent or metastatic head and neck cancer

Predicting treatment outcomes in head and neck cancers with biomarkers

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

Touch Medical Media

The KEYNOTE-001 trial: A breakthrough for pembrolizumab

Recent Advancements in IO Therapy for Head and Neck Cancers

The KEYNOTE-407 Trial in Metastatic Squamous NSCLC

HPV (+) oropharyngeal cancer

KEYNOTE Trial Data: Pembrolizumab’s Role in NSCLC

Pembrolizumab for frontline head and neck cancer: KEYNOTE-048 results

Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC

Targeted Oncology

KEYNOTE-B84: pepinemab + pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma